Drupal.behaviors.print = function(context) {window.print();window.close();}>
Quidel Continues to Advance Trio of MDx Initiatives; On Target to Complete All by End of '13
March 01, 2012
Quidel Continues to Advance Trio of MDx Initiatives; On Target to Complete All by End of '13
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Quidel Unveils Name of Pending POC MDx Platform; Restructures Licensing Deal for Key Tech
October 27, 2011 / PCR Insider
Life Tech to Market Quidel's PCR-Based Infectious Disease Dxs in Europe
September 22, 2011 / PCR Insider
FDA OK of Life Tech, Quidel C. Diff Assay Sets Stage for Future Cleared Tests on QuantStudio Dx
March 21, 2013 / PCR Insider
FDA Clears Quidel C. difficile Assay for Life Tech's QuantStudio Dx and 7500 Fast Dx PCR Instruments
March 18, 2013 / GenomeWeb Daily News
Dx Focus: Quidel RSV/hMPV Test Gets 510(k); Labceutics, Asuragen Partner on BCR-ABL1 Standardization
March 14, 2013 / PCR Insider